drugset / Trial / NCT06802913

A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study

NCT06802913

Phase 0 Recruiting 10 enrolled Woolcock Institute of Medical Research
RandomizedCrossoverOpen-labelTreatment

Summary

The goal of this clinical trial is to explore the potential benefits of an inhaled version of melatonin compared to oral melatonin tablets on adults with insomnia. The main question the trial aims to answer is: does inhaled melatonin affect the sleep profiles of adults with insomnia differently than oral melatonin tablets? 10 Participants will: * Visit the research institute for a screening visit, for an overnight visit at the beginning of each study drug treatment and for a blood collection visit at the end of the conclusion of each study drug treatment period (5 visits in total) * Take 100 µg of inhaled melatonin (2 inhaler puffs) nightly for two weeks * Take a 4 mg of oral melatonin (2 tablets) nightly for two weeks

Timeline

Start
2025-07-01
Primary completion
2025-12
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melatonin Small molecule 100 ug Inhaled
Comparator Melatonin Small molecule 4 mg Oral

Indications